Dual inhibition of Kif15 by oxindole and quinazolinedione chemical probes |
| |
Authors: | Megan E. Dumas Geng-Yuan Chen Nicole D. Kendrick George Xu Scott D. Larsen Somnath Jana Alex G. Waterson Joshua A. Bauer William Hancock Gary A. Sulikowski Ryoma Ohi |
| |
Affiliation: | 1. Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, United States;2. Department of Biomedical Engineering, Pennsylvania State University, State College, PA, United States;3. Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, United States;4. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, United States;5. Vanderbilt Institute of Chemical Biology, Nashville, TN 37232, United States;6. Department of Chemistry, Vanderbilt University, Nashville, TN 37232, United States;7. Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, United States;8. Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, United States;9. Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, United States |
| |
Abstract: | The mitotic spindle is a microtubule-based machine that segregates a replicated set of chromosomes during cell division. Many cancer drugs alter or disrupt the microtubules that form the mitotic spindle. Microtubule-dependent molecular motors that function during mitosis are logical alternative mitotic targets for drug development. Eg5 (Kinesin-5) and Kif15 (Kinesin-12), in particular, are an attractive pair of motor proteins, as they work in concert to drive centrosome separation and promote spindle bipolarity. Furthermore, we hypothesize that the clinical failure of Eg5 inhibitors may be (in part) due to compensation by Kif15. In order to test this idea, we screened a small library of kinase inhibitors and identified GW108X, an oxindole that inhibits Kif15 in vitro. We show that GW108X has a distinct mechanism of action compared with a commercially available Kif15 inhibitor, Kif15-IN-1 and may serve as a lead with which to further develop Kif15 inhibitors as clinically relevant agents. |
| |
Keywords: | Kinesin Mitosis Oxindole Kif15 Eg5 |
本文献已被 ScienceDirect 等数据库收录! |
|